Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation
Europace · 2026
DOI: 10.1093/europace/euag242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2026. Verfasst von Abir Attia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Heart Institute, Faculty of Medicine, 5000 Belanger Street Montreal, Université de Montreal, Montreal, Canada H1T 1C8. Hauptthemen laut MEDLINE: Colchicine, Atrial Fibrillation, Heart Atria, Catheter Ablation. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Montreal Heart Institute Foundation, Quebec Network for Research in Aging, Fonds de recherche du Québec.
Abstract (Originalsprache)
Aims
Atrial fibrillation (AF) is the most frequently diagnosed cardiac arrhythmia. Catheter ablation using radiofrequency cauterization (CA-RFC) performed in the left atrium (LA) aims to isolate electrical sources of AF. This intervention is accompanied by frequent AF recurrences affecting 10% of patients at 30 days and 50% at one-year post-procedure. It has been suggested that inflammation could contribute to AF-recurrence post-CA-RFC. Given its anti-inflammatory and cardioprotective properties, colchicine has been proposed as a potential treatment to prevent AF recurrence post-CA-RFC. Hypothesis RFC can lead to atrial fibrosis, inflammation, and new-onset AF, which may be mitigated by colchicine. Methods and results Male and female Wistar rats (225–275 g) were divided into four groups: Sham or RFC, with or without colchicine (0.25 mg/kg/8 h, intraperitoneally) starting 8 h before surgery until D1 post-procedure. Sham animals underwent surgery without RFC. Electrophysiology and echocardiography assessments were performed on days 1 (D1) and 3 (D3) post-RFC. Colchicine significantly lowered RFC-induced AF vulnerability, improved LA conduction velocity, reduced LA fibrosis, and attenuated LA inflammation post-procedure. Colchicine also prevented RFC-induced CD11c+ macrophages while promoting CD206+ recruitment in the LA.
Conclusion
Colchicine started before RFC may be an innovative strategy to prevent the development of LA arrhythmogenic substrate post-procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Montreal Heart Institute, Faculty of Medicine, 5000 Belanger Street Montreal, Université de Montreal, Montreal, Canada H1T 1C8.
- Department of Medicine, Faculty of Medicine, Université de Montreal, Montreal, Canada.
- Department of Medicine, Faculty of Medicine, 146 rue Léo Saignat, Université de Bordeaux, 33000 Bordeaux, France.
- Department of Pharmacology and Physiology, Université de Montreal, Montreal, Canada.
ORCID-Profile: Charles-Alexandre LeBlanc, Jean-François Tanguay, Jean-Claude Tardif, Martin Aguilar, Roddy Hiram
Förderung
- Montreal Heart Institute Foundation
- Quebec Network for Research in Aging
- Fonds de recherche du Québec
- Canadian Foundation for Innovation
- FRQ Early-career establishment
Zitieren
APA
Attia, A., LeBlanc, C. A., Le Quilliec, E., Xiong, F., Sirois, M. G., Tanguay, J. F., Tardif, J. C., Aguilar, M., & Hiram, R. (2026). Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation. Europace. https://doi.org/10.1093/europace/euag242
Vancouver
Attia A, LeBlanc CA, Le Quilliec E, Xiong F, Sirois MG, Tanguay JF, et al. Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation. Europace. 2026. doi:10.1093/europace/euag242
BibTeX
@article{Attia2026,
author = {Attia, Abir and LeBlanc, Charles-Alexandre and Le Quilliec, Ewen and Xiong, Feng and Sirois, Martin G and Tanguay, Jean-François and Tardif, Jean-Claude and Aguilar, Martin and Hiram, Roddy},
title = {Colchicine initiated before radiofrequency-induced injury attenuates left atrial inflammation, fibrosis, and susceptibility to atrial fibrillation},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag242}
}
EUVIMED